submit to the journals

Lung Cancer Journal Articles, Videos And Insights

Lung Cancer:FEATURED Articles

flipper_slider

Lung Cancer: Latest Articles

Lung Cancer: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
Pembrolizumab—Latest Data on its use as Monotherapy and in Combination with Chemotherapy in Non-small Cell Lung Cancer Katrina Mountfort
Medical Writer, Touch Medical Media, UK
Insight
Durvalumab: First Immunotherapy to be Approved for Stage III Non-small Cell Lung Cancer Katrina Mountfort
Medical Writer, Touch Medical Media, UK

Lung Cancer:FEATURED VIDEOS

Editor's choice

In this interview, at ESMO 2018, Dr Raffaele Califano talks to touchONCOLOGY about epidermal growth factor receptor (EGFR) expression in non-small cell lung cancer (NSCLC). He explains the importance of detecting EGFR activity prior to treatment in order to treat the patient effectively. Dr Califano also discusses the results from several recent trials including the phase III FLAURA trial in mechanisms of acquired resistance, a phase II study of nazartinib in patients with treatment-naive EGFR-mutant NSCLC, and the phase Ib study in teliso-V monotherapy and in combination with erlotinib. Finally, he looks to the future of mechanisms of resistance and how best to tackle them. Questions: 1. What incidence of patients with non-small cell lung cancer (NSCLC) express EGFR, and how do management strategies differ in these patients? (0:11) 2. What new data around EGFR-mutated NSCLC is being presented at this year's ESMO congress, and what are the implications for clinical practice? (0:52) 3. What are the next steps in this field of research? (5:56) Speaker disclosures: Raffaele Califano has nothing to disclose in relation to this interview. Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Martin Edelman from the Fox Chase Cancer Center in Philadelphia, PA, US discusses current treatments and unmet needs in small cell lung cancer and how research into immunotherapy, including dinutuximab and irinotecan as a second-line therapy, can contribute to treatment strategies. 1. What are the most important unmet needs in the treatment of small cell lung cancer (SCLC)? (0:11) 2. What options are available for patients who relapse or are refractory to first-line treatment? (0:38) 3. What factors impact the efficacy of and outcome after second-line treatments for SCLC? (1:29) 4. Could you tell us a little about the recent phase II/III study of dinutuximab and irinotecan for second-line treatment of SCLC? (1:56) 5. What advances have been made in the second-line therapy of SCLC using immunotherapy? (2:45) Speaker disclosures: Martin Edelman has provided consultancy for Precision Oncology. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Lung Cancer:Latest Videos

Video List based on Category on Node Page

Latest Videos

In this interview, at ESMO 2018, Dr Raffaele Califano talks to touchONCOLOGY about epidermal growth factor receptor (EGFR) expression in non-small cell lung cancer (NSCLC). He explains the importance of detecting EGFR activity prior to treatment in order to treat the patient effectively. Dr...
Martin Edelman from the Fox Chase Cancer Center in Philadelphia, PA, US discusses current treatments and unmet needs in small cell lung cancer and how research into immunotherapy, including dinutuximab and irinotecan as a second-line therapy, can contribute to treatment strategies. 1. What...
Jennifer C King, PhD, Director of Science and Research at the Lung Cancer Alliance, Washington, DC, talks to us about unmet needs in non-small cell lung cancer and the role Lung Cancer Alliance plays in supporting patients and research. 1. Could you tell us a little about the services...
Part 2 of 2 - Dr David Heigener discusses the large number of patients that can’t receive targeted therapy or checkpoint inhibitors, and other unmet needs in non-small cell lung cancer (NSCLC). He also gives us his thoughts on liquid biopsy and its use in NSCLC. Filmed at The American Society...
Part 1 of 2 – The first part of our interview with Dr David Heigener highlights the lack of data on combination therapies for EGFR-positive non-small cell lung cancer and the issues with synergistic toxicity. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Part 2 of 2 - Dr Maurice Pérol talks to us about the recent IFCT-GFPC 0502-Eco phase III study in optimization of maintenance therapy in non-small cell lung cancer, by tailoring the treatment according to the response from induction chemotherapy. Filmed at the American Society of Clinical...

LATEST TWEETS

Conference Highlights